Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1345/aph.1C190 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy.
Cancer Res Treat
July 2015
Laboratory of Medical Oncology, Research Institutes of Medical Oncology, The Catholic University of Korea, Seoul, Korea.
Purpose: Dose-limiting toxicities of docetaxel are widely considered to be neutropenia, anemia, skin toxicity, and nausea. One of the factors that limit the use of docetaxel is its unpredictability of inter-individual variation in toxicity.
Materials And Methods: In order to identify the genetic factors that affect the risk of docetaxel-induced toxicities, we recruited patients who received docetaxel chemotherapy.
Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.
J Oncol Pharm Pract
February 2014
Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.
Docetaxel-associated palmar-plantar erythrodysesthesia is rarely reported in literature, particularly when used in the treatment of sarcomas. Here, we report a case of docetaxel-related palmar-plantar erythrodysesthesia in a 28-year-old male with recurrent Ewing sarcoma. Although palmar-plantar erythrodysesthesia has been seen in the literature for 30 years, there has still been little progress in understanding and appropriately addressing this adverse effect.
View Article and Find Full Text PDFDexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?
J Oncol Pharm Pract
June 2012
Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Colchester, VT 05446, USA.
Purpose: To evaluate the clinical literature supporting reduced doses of dexamethasone to prevent taxane hypersensitivity reactions (HSRs), and edema/skin toxicities in respect to docetaxel, when taxanes are given weekly, as opposed to every 3 weeks.
Data Source: Clinical literature of human-controlled clinical trials, accessed through MEDLINE and meeting abstract databases (from 1990 to 2010).
Data Extraction: The retrieved literature was reviewed to include all human clinical trials that recorded adverse effect information with weekly taxanes utilizing reduced-dose or tapering dexamethasone schemas, either prospectively or retrospectively.
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.
Ann Allergy Asthma Immunol
March 2009
Department of Medicine, Division of Allergy and Immunology, VA Greater Los Angeles Healthcare System/University of California Los Angeles, Los Angeles, California 90073, USA.
Objectives: To review clinical hypersensitivity reactions related to common cancer chemotherapy agents and to discuss potential management strategies.
Data Sources: PubMed searches were performed for articles published from 1970 to 2008 regarding hypersensitivity to cancer chemotherapy and related agents using the keywords hypersensitivity, allergy, chemotherapy, platinums, taxanes, asparaginase, epipodophyllotoxins, and procarbazine. Retrieved articles were surveyed for additional citations.
Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel.
Acta Oncol
June 2004
Department of Oncology, Helsinki University Central Hospital, Finland.
Docetaxel-related skin toxicity, oral and gastrointestinal mucosal toxicity, and changes in blood cell counts were investigated as predictive factors for major infections in 143 women treated with 3-weekly docetaxel (100 mg/m2) as second-line therapy for metastatic breast cancer in a randomized trial. Each patient with a major infection (n = 37) was compared with two controls. Skin toxicity (odds ratio 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!